Target intelligence / Profile preview

Interleukin-2 receptor subunit gamma (IL2RG)

Target
IL2RG
Molecular classification
Receptor, Type I cytokine receptor
01

Overview

Interleukin-2 receptor subunit gamma (IL2RG), also known as the common gamma chain (gamma-c) or CD132, is a vital type I cytokine receptor subunit shared by the receptor complexes of at least six interleukins: IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. It is constitutively expressed on most lymphocyte populations, including T cells, B cells, and natural killer (NK) cells, where it plays an indispensable role in lymphocyte development, survival, and immune homeostasis. Upon cytokine binding, IL2RG associates with cytokine-specific receptor subunits and activates downstream signaling cascades, primarily via the Janus kinase 3 (JAK3) and signal transducer and activator of transcription 5 (STAT5) pathways. Mutations in the IL2RG gene lead to X-linked severe combined immunodeficiency (X-SCID), a life-threatening condition characterized by a profound lack of functional T, B, and NK cells. In therapeutic contexts, IL2RG is targeted by both agonists and antagonists; IL2RG-dependent cytokine agonists (such as aldesleukin and IL-15 superagonists) are utilized in cancer immunotherapy to boost anti-tumor immune responses, whereas IL2RG antagonists and multi-cytokine inhibitors (such as REGN7257 and EQ101) are being developed to treat autoimmune disorders, transplant rejection, and T-cell malignancies by suppressing aberrant immune activation.

Other names
CD132Common gamma chainIL-2RGCytokine receptor common subunit gammagammaCp64SCIDXSCIDX1IMD4CIDX
02

Mechanism of action

Inhibition of common gamma chain (CD132) cytokine signaling to suppress T-cell and NK-cell activation; Activation of the IL-2/IL-15 receptor complex to stimulate cytotoxic immune responses.

03

Biological functions

Signal transductionImmune responseCell proliferationCell survivalLymphocyte development
04

Disease associations

InfectionCancerInflammationAutoimmune diseaseImmunodeficiency
05

Safety considerations

ImmunosuppressionInfection riskLymphopeniaVascular leak syndromeAutoimmunityCytokine release syndrome
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

CD132 expressionT regulatory cell (Treg) countNatural killer (NK) cell countCD8+ central memory T cell countJAK3 phosphorylationSTAT5 phosphorylation

Beyond the preview

Go deeper on Interleukin-2 receptor subunit gamma (IL2RG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-2 receptor subunit gamma (IL2RG).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call